UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tumor treating fields: a new frontier in cancer therapy

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.86-95

2013

Volltextzugriff (PDF)

Incorporating Bortezomib into the Treatment of Lung Cancer

Clinical cancer research, 2007-08, Vol.13 (15), p.4647s-4651s

2007

Volltextzugriff (PDF)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Skeletal muscle, 2019-05, Vol.9 (1), p.12-10, Article 12

2019

Volltextzugriff (PDF)

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Clinical cancer research, 2007-10, Vol.13 (20), p.6175-6181

2007

Volltextzugriff (PDF)

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

Journal of thoracic oncology, 2011-12, Vol.6 (12), p.2112-2119

2011

Volltextzugriff (PDF)

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

Journal of thoracic oncology, 2011-04, Vol.6 (4), p.774-780

2011

Volltextzugriff (PDF)

Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma

Seminars in oncology, 2014-06, Vol.41, p.S1-S14

2014

Volltextzugriff (PDF)

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5242-5246

2006

Volltextzugriff (PDF)

Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A Summary

The oncologist (Dayton, Ohio), 2007-09, Vol.12 (9), p.1070-1083

2007

Volltextzugriff (PDF)

Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

In vivo (Athens), 2022-07, Vol.36 (4), p.1615-1627

2022

Volltextzugriff (PDF)

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

Journal of thoracic oncology, 2009-12, Vol.4 (12), p.1466-1472

2009

Volltextzugriff (PDF)

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Clinical cancer research, 2007-08, Vol.13 (15), p.4583s-4588s

2007

Volltextzugriff (PDF)

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Journal of thoracic oncology, 2009-01, Vol.4 (1), p.87-92

2009

Volltextzugriff (PDF)

Pharmacodynamic Separation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy in Non–Small-Cell Lung Cancer

Clinical lung cancer, 2006-05, Vol.7 (6), p.385-388

2006

Volltextzugriff (PDF)

Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation

Journal of thoracic oncology, 2009-07, Vol.4 (7), p.862-868

2009

Volltextzugriff (PDF)

Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study

Investigational new drugs, 2007-08, Vol.25 (4), p.351-355

2007

Volltextzugriff (PDF)

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

Investigational new drugs, 2013-12, Vol.31 (6), p.1587-1591

2013

Volltextzugriff (PDF)

Schedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation

Clinical lung cancer, 2007-11, Vol.8 (9), p.548-553

2007

Volltextzugriff (PDF)

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

Journal of thoracic oncology, 2006-11, Vol.1 (9), p.996-1001

2006

Volltextzugriff (PDF)

Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)

Journal of thoracic oncology, 2011-10, Vol.6 (10), p.1741-1745

2011

Volltextzugriff (PDF)

Inverse dynamics modelling of upper-limb tremor, with cross-correlation analysis

Healthcare technology letters, 2014-06, Vol.1 (2), p.59-63

2014

Volltextzugriff (PDF)

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2005-08, Vol.49 (2), p.163-170

2005

Volltextzugriff (PDF)

Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma

Clinical lung cancer, 2013-07, Vol.14 (4), p.351-355

2013

Volltextzugriff (PDF)

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

Investigational new drugs, 2011-08, Vol.29 (4), p.680-687

2011

Volltextzugriff (PDF)

1 – 25 von 602

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(559)
Mit Volltextzugriff
(509)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(601)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Monthly Notices Of The Royal Astronomical Society
(27)
Journal Of Thoracic Oncology
(23)
The Lancet
(18)
Clinical Lung Cancer
(14)
Biology Of Blood And Marrow Transplantation
(12)
Tetrahedron: Asymmetry
(12)
Cheminform
(11)
Tetrahedron
(10)
Nature
(9)
Clinical Cancer Research
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Tumor treating fields: a new frontier in cancer therapy

Incorporating Bortezomib into the Treatment of Lung Cancer

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma

The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712

Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A Summary

Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Pharmacodynamic Separation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy in Non–Small-Cell Lung Cancer

Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation

Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

Schedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327)

Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)

Inverse dynamics modelling of upper-limb tremor, with cross-correlation analysis

Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer

Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

Suchergebnisse filtern